Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin names Rashmi Ramchandani Chief Accounting Officer, effective January 19, 2026

Neutral Impact 2 of 5 leadership Written later

BioMarin announced that Rashmi Ramchandani will become Vice President and Chief Accounting Officer on January 19, 2026, taking over as principal accounting officer from CFO Brian Mueller, who remains CFO. The filing sets out her pay package, including a $460,000 base salary and a $400,000 sign-on bonus, which matters to shareholders as a routine finance leadership change with defined compensation.

Key points

  • Ramchandani's effective start date is January 19, 2026; she becomes principal accounting officer from Brian Mueller, who stays EVP and CFO.
  • Compensation includes a $460,000 base salary, a $400,000 sign-on bonus, and a 45% target bonus payout starting in 2026.
  • Equity awards include RSUs valued at $1,050,000 and $400,000, and stock options valued at $450,000.
  • Ramchandani previously held accounting roles at Gilead Sciences and was a controller at Strava, Inc.

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECDec 17, 2025, 4:06 PM ET
Accession number0001193125-25-322704

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 17, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.